In the rapidly advancing field of precision oncology, a critical bottleneck in patient care is selecting the most relevant molecular test and using it to identify and accurately interpret the genetic alterations in an individual's cancer. Despite the wealth of genomic information available, these challenges can lead to delays in critical treatment, hindering the promise of our field.
This white paper from Velsera discusses the challenges in multigene analysis in the field of precision oncology, regulatory differences between IVDs and LDTs, reimbursement considerations, and solutions offered by Velsera to navigate these challenges.
Offered Free by: Velsera
See All Resources from: Velsera